awmsg logo



ranolazine (Ranexa®)


Reference No. 723

Publication date:
03/02/2011


Appraisal information

ranolazine (Ranexa®) 375 mg prolonged-release tablet
ranolazine (Ranexa®) 500 mg prolonged-release tablet
ranolazine (Ranexa®) 750 mg prolonged-release tablet


Company: A. Menarini Farmaceutica Internazionale SRL
BNF category: Cardiovascular system
NMG meeting date: 17/11/2010
AWMSG meeting date: 15/12/2010
   
   
Submission Type: Resubmission
Status: Recommended with restrictions
Advice No: 1710
Ministerial ratification: 27/01/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Ranolazine (Ranexa®) as an add-on therapy is recommended as an option for restricted use within NHS Wales for the symptomatic treatment of patients with stable angina pectoris. Treatment should be initiated by a Cardiologist. Ranolazine (Ranexa®) should be restricted for use in patients who remain symptomatic despite treatment with all other pharmacological anti-anginal therapies and where revascularisation has been considered and undertaken or is not considered appropriate.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download